Hepatitis B virus core antigen epitopes presented by HLA‐A2 single‐chain trimers induce functional epitope‐specific CD8+ T‐cell responses in HLA‐A2·1/Kb transgenic mice

Authors:

Abstract
Summary: The potency of CD8+ cytotoxic T lymphocyte (CTL) responses toward core antigen has been shown to affect the outcomes of hepatitis B virus (HBV) infection. Since single‐chain trimers (SCT) composed of peptide epitope β2‐microglobulin (β2m) and major histocompatiblity complex (MHC) class I heavy chain covalently linked together in a single molecule have been shown to stimulate efficient CTL responses, we investigated the properties of human leucocyte antigen (HLA)‐A2 SCTs encoding the HBV core antigen (HBcAg) epitopes C18−27 and C107−115. Transfection of NIH‐3T3 cells with pcDNA3.0‐SCT‐C18−27 and SCT‐C107−115 leads to stable presentation of HBcAg epitopes at the cell surface. HLA‐A2.1/Kb transgenic mice vaccinated with the SCT constructs, either as a DNA vaccine alone or followed by a boost with recombinant vaccinia virus, were shown to generate HBcAg‐specific CTL responses by enzyme‐linked immunospot assay (ELISPOT) and in vitro interferon‐γ release experiments. HBcAg‐specific CTLs from vaccinated HLA‐A2.1/Kb transgenic mice were able to inhibit HBV surface and e antigen expression as indicated by HepG2.2.15 cells. Our data indicate that a DNA vaccine encoding a human HLA‐A2 SCT with HBV epitopes can lead to stable, enhanced HBV core antigen presentation, and may be useful for the control of HBV infection in HLA‐A2‐positive HBV carriers.

This publication has 29 references indexed in Scilit: